Multiple sites of thrombosis without thrombocytopenia after a second dose of Pfizer-BioNTech COVID-19 vaccine

In the current international scientific panorama, rare cases of venous thrombotic complications following mRNA vaccine administration have been reported, consisting mainly of cerebral sinus thromboses and acute venous thromboembolism. The present paper describes the case of a 75-year-old woman in go...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of immunopathology and pharmacology Vol. 36; p. 3946320221128534
Main Authors Scendoni, Roberto, Petrelli, Cristina, Giustozzi, Mauro, Logullo, Francesco O
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.09.2022
Sage Publications Ltd
Subjects
Case Report
COVID-19 vaccines
mRNA
mRNA vaccines
Pharmacovigilance
Risk factors
Thrombocytopenia
Thromboembolism
Thrombosis
computed tomography
COVID-19 infection
thromboembolism
thrombocytopenia
venous thrombosis
Pfizer-BioNTech vaccine
Online AccessGet full text

Cover

More Information
Summary:In the current international scientific panorama, rare cases of venous thrombotic complications following mRNA vaccine administration have been reported, consisting mainly of cerebral sinus thromboses and acute venous thromboembolism. The present paper describes the case of a 75-year-old woman in good health who developed cerebral venous thrombosis, deep venous thrombosis, and bilateral pulmonary emboli after receiving a second dose of Pfizer-BioNTech COVID-19 vaccine. A series of laboratory tests performed during hospitalization yielded interesting results, allowing us to exclude thrombophilic risk factors and to certify the absence of thrombocytopenia in the patient. Although COVID-19 vaccination is the most important tool in stopping the pandemic, pharmacovigilance is crucial for detecting potential multisystem thrombotic events, even for mRNA vaccines.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0394-6320
2058-7384
DOI:10.1177/03946320221128534